Genetic alterations in the NO-cGMP pathway and cardiovascular risk

Keyphrases

• Associated Proteins 50%
• Blood Pressure 50%
• Cardiovascular Disease 50%
• Cardiovascular Risk 100%
• Chromosomal Locus 50%
• Coronary Artery Disease 50%
• Coronary Risk Factors 100%
• Endothelial Nitric Oxide Synthase (eNOS) 50%
• Genetic Findings 50%
• Genetic Modification 100%
• Genome-wide Association Study 50%
• GUCY1A3 50%
• Inositol 1,4,5-trisphosphate Receptor (IP3R) 50%
• MRVI1 50%
• NO-cGMP Pathway 100%
• NO-cGMP Signaling 50%
• NOS3 50%
• PDE3A 50%
• PDE5A 50%
• Phosphodiesterase 3 (PDE3) 50%
• Phosphodiesterase Type 5 Inhibitors 50%
• Risk Factors 50%
• Risk Genes 50%
• Soluble Guanylyl Cyclase 50%
• Therapeutic Implications 50%

Biochemistry, Genetics and Molecular Biology

• Blood Pressure 100%
• Gene Mutation 100%
• Genetics 100%
• Genome-Wide Association Study 100%
• Guanylate Cyclase 100%
• Inositol 1,4,5 Trisphosphate Receptor 100%
• Nitric Oxide Synthase 100%
• Phosphodiesterase 100%

Pharmacology, Toxicology and Pharmaceutical Science

• Atherosclerosis 33%
• Cardiovascular Disease 33%
• Cardiovascular Risk 100%
• Coronary Artery Disease 100%
• Endothelial Nitric Oxide Synthase 33%
• Guanylate Cyclase 33%
• Inositol 1,4,5 Trisphosphate Receptor 33%
• Phosphodiesterase 33%